376 related articles for article (PubMed ID: 23330781)
1. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
3. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
4.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
6. Somatic driver mutations in melanoma.
Reddy BY; Miller DM; Tsao H
Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for melanoma: rational combinatorial approaches.
Kwong LN; Davies MA
Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
11. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
13. [What's new in dermato-oncology?].
Basset-Séguin N
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S253-62. PubMed ID: 22202647
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
15. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
16. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
18. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
19. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
20. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
